Go to the list of all blogs
Anna G's Avatar
published in Blogs
Apr 06, 2021
TickeronGET DAILY SIGNALS
Golden Nugget Online Gaming (GNOG, $15.57) gets buy rating from Jefferies

Golden Nugget Online Gaming (GNOG, $15.57) gets buy rating from Jefferies

Golden Nugget Online Gaming  shares got a buy rating from a Jefferies analyst  who initiated coverage of the online gambling/sports entertainment company.

Analyst David Katz gave a $28 price target, citing “demonstrated leadership-level assets and capabilities."

"The magnitude and productivity prospects of the iGaming market have not been fully appreciated by [Wall] Street, ... and GNOG's positioning and product strength have been proven in New Jersey," Katz said.

According to Katz, Golden Nugget is a “compelling investment”. He mentioned that the company’s 2020 performance in the nascent, competitive NJ market (revenue of $91.1 million and Ebitda of $28.9 million) “provides a framework for the future."

Katz mentioned factors such as ownership of the Golden Nugget brand, access to 10 markets, breadth of product with more than 870 titles, innovation, and demonstrated customer-relationship-management capabilities, as he said Golden Nugget brings "leadership-level assets." 

Related Ticker: GNOG
Related Portfolios: THE GAMING INDUSTRY
View a ticker or compare two or three
Ask AI
VS
Compare
VS
Compare
Interact to see
Advertisement
A.I.Advisor
published price charts
Last 5 trading days
View AI-Driven Trading for GNOG
A.I. Advisor
published General Information

General Information

an operator of food ordering and restaurant management mobile application

Industry CasinosGaming

Profile
Details
Industry
Internet Retail
Address
1510 West Loop South
Phone
+1 713 850-1010
Employees
259
Web
https://www.gnoginc.com
Interact to see
Advertisement

Novo Nordisk vs. Eli Lilly vs. Pfizer: Earnings Preview Ahead of the GLP-1 Showdown

Novo Nordisk (NVO) reports Q4 2025 earnings on February 4, 2026, with consensus estimates of $11.96 billion in revenue and $0.89 EPS, reflecting a moderation in GLP-1 growth. Eli Lilly (LLY) is expected to report around the same time, with projections of $17.87 billion in revenue and $6.99 EPS, driven by continued volume gains from Mounjaro and Zepbound.
NVOLLYPFE#PharmaceuticalsMajor
Arthur Evans, expert
Feb 06, 2026

Banco Santander vs. Bank of America: Earnings Preview as Global Banking Momentum Faces a Reality Check

Banco Santander (SAN) reports Q4 2025 earnings on February 4, 2026, following record nine-month attributable profit of €10.3 billion, up 11% year over year.
SANBAC#MajorBanks
Arthur Evans, expert
Feb 06, 2026

Uber vs. Lyft: Earnings Preview as Q4 Results Put Ride Demand and Margins in Focus

Uber (UBER) reports Q4 2025 earnings on February 4, 2026, with consensus estimates of $0.78 EPS and $14.32 billion in revenue, up about 20% year over year.
UBERLYFT#PackagedSoftware
Arthur Evans, expert
Feb 08, 2026

Qualcomm (QCOM) Earnings Preview: Modest Growth Expected Amid AI Momentum

Qualcomm’s Q1 FY2026 report, covering the period ended December 28, 2025, arrives amid a pivotal shift in the semiconductor landscape. While handset growth moderates, the company is expanding in automotive, IoT, and AI-enabled devices.
QCOM#Semiconductors
Arthur Evans, expert
Feb 08, 2026

UBS vs HSBC: Earnings Preview as Q4 Results Could Shift European Bank Sentiment

UBS Group AG reports Q4 2025 earnings on February 4, 2026, with consensus EPS ranging $0.25–$0.67 and revenue around $11.62 billion, down YoY. HSBC Holdings plc reports Q4 earnings on February 25, 2026, with consensus EPS ~$1.57; Q3 showed resilient net interest income despite $1.4B in legal provisions.
UBSHSBC#MajorBanks
Arthur Evans, expert
Feb 09, 2026

BSX vs MDT vs SYK: MedTech Earnings Preview as Q4 Results Put Growth and Margins in Focus

Boston Scientific’s Q4 caps a transformative year, driven by ~15.5% organic growth from WATCHMAN, FARAPULSE electrophysiology, and MedSurg expansions. As a leader in minimally invasive devices, BSX’s results set the benchmark against Medtronic and Stryker—diversified medtech giants navigating tariffs, procedural rebounds, and innovation.
BSXSYKMDT#MedicalNursingServices
Arthur Evans, expert
Feb 08, 2026

Arm Holdings (ARM) Earnings Preview: AI Demand Drives Royalty Growth Amid Elevated Expectations

Arm, the leading provider of energy-efficient processor designs powering over 99% of smartphones and expanding into AI data centers, faces high scrutiny in Q3 FY2026 (ending Dec 31, 2025). After a strong Q2 with record royalty and licensing revenue, investors are focused on whether AI demand will continue to drive robust growth.
ARM#Semiconductors
Arthur Evans, expert
Feb 06, 2026

Datadog (DDOG) Stock Analysis: AI Growth Narrative Intact After Sharp Pullback

Datadog (DDOG) has come under pressure in recent sessions as volatility across the software sector weighs on sentiment ahead of earnings. Trading in the $108–120 range following a pullback from highs near $200, the stock reflects a disconnect between near-term market caution and resilient underlying fundamentals.
DDOG#PackagedSoftware
Dem Sem, expert
Feb 11, 2026

Starbucks (SBUX) Stock Analysis: Turnaround Momentum Gains Traction

Starbucks shares have shown renewed strength in recent trading, rebounding from earlier lows within a 52-week range of $75.50 to $117.46. The recovery reflects improving comparable sales trends and a return to transaction growth, suggesting early progress from operational initiatives aimed at reconnecting with customers.
SBUX#Restaurants
Dem Sem, expert
Feb 10, 2026

DoorDash (DASH) Stock Analysis: Managing Volatility Amid Delivery Sector Pressures

DoorDash holds a Strong Buy consensus from 33 analysts, with an average 12-month price target of $280.82, implying more than 40% upside from recent trading levels.
DASH#InternetRetail
Dem Sem, expert
Feb 11, 2026

Amazon.com (AMZN) Q4 2025 Earnings Recap: Revenue Beat Overshadowed by AI Capex Shock

Amazon’s Q4 report capped a strong year marked by accelerating cloud growth, steady retail execution, and expanding advertising profitability. The results reinforced Amazon’s positioning as a core beneficiary of enterprise AI demand, particularly through AWS, while highlighting improving operating leverage across the broader business.
AMZN#InternetRetail
Dem Sem, expert
Feb 09, 2026

ConocoPhillips (COP) Q4 2025 Earnings Recap: Production Gains Cushion EPS Miss

ConocoPhillips reported Q4 2025 adjusted EPS of $1.02, below consensus of $1.08, driven by weaker realized commodity prices.
COP#OilGasProduction
Dem Sem, expert
Feb 13, 2026

Intercontinental Exchange (ICE) Q4 2025 Earnings Recap: Record Revenues Drive 14% EPS Growth

ICE reported Q4 2025 net revenues of $2.5 billion, up 8% year-over-year, capping 20 consecutive years of record annual revenues at $9.9 billion.
ICE#FinancialPublishingServices
Dem Sem, expert
Feb 08, 2026

LLY vs JNJ Stock Comparison: Q4 2025 Earnings and 2026 Guidance

Eli Lilly’s Q4 results highlight explosive growth from GLP-1 therapies, cementing leadership in obesity and diabetes. The company’s strong revenue beat and robust 2026 guidance illustrate high-growth pharma dynamics. Johnson & Johnson, in contrast, exemplifies a diversified healthcare strategy, combining pharmaceuticals, MedTech, and consumer health for steady expansion.
LLYJNJ#PharmaceuticalsMajor
Dem Sem, expert
Feb 10, 2026

ABBV vs MRK vs LLY Stock Comparison: Q4 2025 Earnings and 2026 Outlook

Eli Lilly (LLY), AbbVie (ABBV), and Merck (MRK) all reported strong Q4 2025 earnings, but the market reacted differently to each, reflecting variations in growth profiles, product concentration, and sector dynamics. AbbVie delivered Q4 revenue of $16.62 billion, up 10% year-over-year, with full-year revenue reaching $61.2 billion, an 8.6% increase. Adjusted EPS came in at $2.71, surpassing consensus, though shares dipped following the report amid ongoing Humira concerns
ABBVMRKLLY#PharmaceuticalsMajor
Dem Sem, expert
Feb 08, 2026

NVO vs NVS Stock Comparison: Q4 2025 Earnings Recap and Outlook

Novo Nordisk (NVO) reported Q4 2025 EPS of $1.02, surpassing estimates of $0.92, with revenue of $12.53B vs $11.99B expected. Full-year 2025 sales rose 10% at constant exchange rates (CER) to DKK 309B, but 2026 guidance anticipates a 5–13% decline at CER due to pricing pressures. Novartis (NVS) posted Q4 core EPS of $2.03, beating $1.99 estimates; net sales of $13.34B slightly missed consensus. FY sales grew 8%, with core EPS up 17% to $8.98.
NVONVS#PharmaceuticalsMajor
Dem Sem, expert
Feb 11, 2026

MUFG vs HSBC Stock Comparison: Earnings Preview Amid Global Banking Shifts

MUFG (Mitsubishi UFJ Financial Group) posted Q3 FY2026 profits of ¥1.81 trillion, up 3.7% YoY, on track for its full-year target of ¥2.1 trillion. HSBC is set to report Q4 FY2025 earnings on Feb 25, 2026, with consensus EPS around $1.60; recent quarters showed resilient net interest income (NII) supported by Asia wealth growth.
MUFGHSBC#MajorBanks
Dem Sem, expert
Feb 13, 2026

Gogo Inc. (GOGO) Stock Analysis: Balancing 5G Momentum Against Competitive Pressures

Gogo shares continue to trade near 52-week lows around $4, weighed down by competitive threats from Starlink and slower-than-anticipated AVANCE system upgrades. William Blair downgraded the stock to Market Perform in December 2025, citing leverage concerns and intensifying rivalry in in-flight connectivity.
GOGO#MajorTelecommunications
Abhoy Sarkar, expert
Feb 15, 2026

Quantum Computing Inc. (QUBT) Stock Analysis: Photonics Strategy Redefines Growth Outlook

Quantum Computing Inc. completed a $110 million acquisition of Luminar Semiconductor on February 2, significantly strengthening its photonics and manufacturing capabilities. Shares have traded with elevated volatility, peaking near $12.70 in mid-January before retreating to the $9 range amid heavy volume.
QUBT#ComputerProcessingHardware
Abhoy Sarkar, expert
Feb 16, 2026

Energy Recovery Inc. (ERII) Stock Analysis: Capitalizing on Rising Desalination Demand

ERII shares have remained resilient, trading near $15.47 ahead of Q4 and full-year 2025 earnings scheduled for February 25, 2026. Q3 2025 results exceeded expectations, with revenue of $32 million and EPS of $0.07, despite year-over-year declines tied to project timing.
ERII#IndustrialSpecialties
Abhoy Sarkar, expert
Feb 20, 2026